DBV Stock Overview
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
DBV Technologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€5.30|
|52 Week High||€13.69|
|52 Week Low||€3.91|
|1 Month Change||-7.89%|
|3 Month Change||-43.91%|
|1 Year Change||28.32%|
|3 Year Change||-80.19%|
|5 Year Change||-92.21%|
|Change since IPO||-40.96%|
Recent News & Updates
Will DBV Technologies (EPA:DBV) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|DBV||FR Biotechs||FR Market|
Return vs Industry: DBV exceeded the French Biotechs industry which returned 7.2% over the past year.
Return vs Market: DBV exceeded the French Market which returned 23.7% over the past year.
|DBV Average Weekly Movement||10.6%|
|Biotechs Industry Average Movement||6.8%|
|Market Average Movement||4.6%|
|10% most volatile stocks in FR Market||9.3%|
|10% least volatile stocks in FR Market||2.6%|
Stable Share Price: DBV is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: DBV's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordetella pertussis.
DBV Technologies Fundamentals Summary
|DBV fundamental statistics|
Is DBV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DBV income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.25|
|Net Profit Margin||-7,904.09%|
How did DBV perform over the long term?See historical performance and comparison
Is DBV Technologies undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DBV (€5.3) is trading below our estimate of fair value (€53.83)
Significantly Below Fair Value: DBV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DBV is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: DBV is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DBV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DBV is good value based on its PB Ratio (2.8x) compared to the FR Biotechs industry average (4x).
How is DBV Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DBV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).
Earnings vs Market: DBV is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: DBV's is expected to become profitable in the next 3 years.
Revenue vs Market: DBV's revenue (96% per year) is forecast to grow faster than the French market (6.6% per year).
High Growth Revenue: DBV's revenue (96% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DBV's Return on Equity is forecast to be high in 3 years time
How has DBV Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DBV is currently unprofitable.
Growing Profit Margin: DBV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DBV is unprofitable, and losses have increased over the past 5 years at a rate of 0.8% per year.
Accelerating Growth: Unable to compare DBV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DBV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).
Return on Equity
High ROE: DBV has a negative Return on Equity (-105.76%), as it is currently unprofitable.
How is DBV Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: DBV's short term assets ($110.1M) exceed its short term liabilities ($33.8M).
Long Term Liabilities: DBV's short term assets ($110.1M) exceed its long term liabilities ($20.2M).
Debt to Equity History and Analysis
Debt Level: DBV has more cash than its total debt.
Reducing Debt: DBV's debt to equity ratio has reduced from 1.9% to 0.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DBV has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: DBV has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.3% each year
What is DBV Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DBV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DBV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DBV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DBV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DBV's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Daniel Tassé (61 yo)
Mr. Daniel Tasse had been an Independent Non-Executive Director of Indivior PLC since August 2014 until May 6, 2021 and had been its Senior Independent Director since September 30, 2016 until May 6, 2021....
CEO Compensation Analysis
Compensation vs Market: Daniel's total compensation ($USD2.06M) is above average for companies of similar size in the French market ($USD511.56K).
Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.
Experienced Management: DBV's management team is considered experienced (2.5 years average tenure).
Experienced Board: DBV's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
DBV Technologies S.A.'s employee growth, exchange listings and data sources
- Name: DBV Technologies S.A.
- Ticker: DBV
- Exchange: ENXTPA
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €291.378m
- Shares outstanding: 54.96m
- Website: https://www.dbv-technologies.com
Number of Employees
- DBV Technologies S.A.
- 177-181 Avenue Pierre Brossolette
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/30 21:41|
|End of Day Share Price||2021/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.